| imfinzi durvalumab biggest company | 1.18 | 0.4 | 5065 | 34 | 92 |
| imfinzi durvalumab biggest comparison | 0.44 | 0.6 | 205 | 37 | 1 |
| imfinzi durvalumab biggest customer | 0.15 | 1 | 3332 | 35 | 44 |
| imfinzi durvalumab biggest commercial | 0.37 | 1 | 6582 | 37 | 87 |
| imfinzi durvalumab biggest collaboration | 0.74 | 0.4 | 8961 | 40 | 32 |
| imfinzi durvalumab biggest competitor in cost | 0.09 | 0.2 | 3650 | 45 | 95 |
| imfinzi durvalumab biggest competitor | 1.15 | 0.4 | 138 | 37 | 92 |
| imfinzi durvalumab biggest clinical trial | 1.47 | 0.2 | 6845 | 41 | 12 |
| imfinzi durvalumab biggest controversy | 1.31 | 0.1 | 4778 | 38 | 31 |
| imfinzi durvalumab biggest challenge | 1.22 | 0.5 | 1377 | 36 | 48 |
| durvalumab imfinzi package insert | 0.56 | 0.5 | 7110 | 33 | 37 |
| j code for imfinzi durvalumab | 1.41 | 0.4 | 3428 | 29 | 3 |
| imfinzi durvalumab side effects | 0.01 | 0.7 | 6569 | 31 | 53 |
| cpt code for durvalumab imfinzi | 0.57 | 1 | 2619 | 31 | 89 |
| imfinzi biggest competitor in clinical trials | 1.19 | 1 | 6136 | 45 | 55 |
| imfinzi biggest competitor in cost | 1.16 | 0.7 | 5506 | 34 | 23 |
| imfinzi biggest competitor in market share | 1.09 | 0.4 | 1205 | 42 | 36 |
